Heterocyclic amine derivatives

A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I

• wherein
• R1 is hydrogen, lower alkyl, halogen, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen, cyano, nitro, C3-6-cycloalkyl, —CH2—C3-6-cycloalkyl, —O—CH2—C3-6-cycloalkyl, —O—(CH2)2—O-lower alkyl, S(O)2CH3, SF5, —C(O)NH-lower alkyl, phenyl, —O-pyrimidinyl, optionally substituted by lower alkoxy substituted by halogen, or is benzyl, oxetanyl or furanyl;
• m is 1 or 2;
• Ar is aryl or heteroaryl, selected from the group consisting of naphthyl, pyrimidinyl, benzothiazolyl, quinolinyl, quinazolinyl, benzo[d][1.3]dioxolyl, 5,6,7,8-tetrahydro-quinazolinyl, pyrazolyl, pyrazinyl, pyridazinyl, and 1,3,4-oxadiazolyl;
• Y is a bond, —CH2—, —CH2CH2—, —CH(CF3)— or —CH(CH3)—;
• R2 is hydrogen or lower alkyl;
• A is CR or N;
• and R is hydrogen, cyano, halogen or lower alkyl;
• R′ is hydrogen or halogen;
• with the proviso that when R1 is halogen, A is CH;
• B is CH or N;
• n is o, 1 or 2;
• and
• X is a bond, —CH2— or —O—;
• or a pharmaceutical active acid addition salt thereof
• and a pharmaceutically acceptable carrier.